.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Talha Munir, MBChB, PhD

Articles

Zanubrutinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis

July 8th 2024

An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.